510(k) device
i-STAT TBI Plasma cartridge with the i-STAT Alinity System
Abbott Laboratories · Brain Trauma Assessment Test (QAT, Class II) · First FDA decision Jan 8, 2021, newest Jan 8, 2021Traumatic brain injury and concussion
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
Breakthrough-designated
Device trials
0
Naming "i-STAT TBI Plasma"
MAUDE reports
0
Brand "i-STAT TBI Plasma", since 2015
PubMed studies
7
Mentioning "i-STAT TBI Plasma"
AI summary across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- i-STAT TBI Plasma cartridge with the i-STAT Alinity SystemBreakthrough510(k)
K201778 · Decided Jan 8, 2021 · 192 days after receipt
Device type: Brain Trauma Assessment Test (QAT) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "i-STAT TBI Plasma", any status and sponsor, newest update first.
No registered device study names "i-STAT TBI Plasma".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "i-STAT TBI Plasma", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QAT
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "i-STAT TBI Plasma"[tiab]. The summary above synthesizes these.
- UCH-L1 and GFAP Testing (i-STAT TBI Plasma) for the Detection of Intracranial Injury Following Mild Traumatic Brain Injury.
Middleton J · Am Fam Physician · 2022
- Glial Fibrillary Acidic Protein and Ubiquitin C-Terminal Hydrolase L1 for Acute Traumatic Intracranial Lesions: The PIONEER Diagnostic Accuracy Study.
Roberts NB, Xie T, Falk H, et al. · Ann Emerg Med · 2026
- Maximizing the Clinical Value of Blood-Based Biomarkers for Mild Traumatic Brain Injury.
Rauchman SH, Pinkhasov A, Gulkarov S, et al. · Diagnostics (Basel) · 2023Review
- Use of plasma-based brain biomarkers in the emergency department to rule out the need for unnecessary head CT imaging in acute mild traumatic brain injury patients.
Elkhodair S, Lalor J, Altaher M, et al. · Am J Emerg Med · 2026Observational Study
- Evaluation of Acute Glial Fibrillary Acidic Protein and Ubiquitin C-Terminal Hydrolase-L1 Plasma Levels in Traumatic Brain Injury Patients with and without Intracranial Lesions.
Biberthaler P, Musaelyan K, Krieg S, et al. · Neurotrauma Rep · 2021
- Comparability of GFAP and UCH-L1 Measurements Using Handheld and Core Laboratory TBI Plasma Tests and Their Diagnostic Performance for Traumatic Intracranial Lesions.
Roberts NB, Gherasim C, Li K, et al. · J Appl Lab Med · 2026Comparative Study
- Integration of GFAP/UCH-L1 Testing into an Emergency Department Concussion Pathway and Calculator to Model TBI Biomarker Impact on Time.
Wilson JW, Bailey G, Baker M, et al. · Neurotrauma Rep · 2026
Other devices of this type
Also filed under product code QAT.
- Vidas Tbi (Gfap, UCH-L1)bioMerieux, Inc. · 510(k) 2024
- i-STAT TBI Cartridge with the i-STAT Alinity SystemAbbott Point of Care · 510(k) 2024
- TbiAbbott Laboratories · 510(k) 2023
- Traumatic brain injury (TBI) testAbbott Laboratories · 510(k) 2023
- Banyan BTIBanyan Biomarkers, Inc. · De Novo 2018
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.